Antengene Corporation Limited (SEHK: 6996.HK), a prominent global biopharmaceutical company focused on innovative therapies in hematology and oncology, and Hansoh Pharmaceutical Group Company Limited (SEHK: 3692.HK), a leading pharmaceutical company specializing in major disease treatments including oncology, infectious diseases, CNS disorders, metabolic diseases, and autoimmune diseases, have jointly announced a strategic collaboration. The partnership is centered around the commercialization of XPOVIO® in mainland China.

Dr. Jay Mei, the Founder, Chairman, and CEO of Antengene, expressed confidence in the potential of XPOVIO® as a groundbreaking XPO1 inhibitor for China. He emphasized that this collaboration with Hansoh Pharma would utilize their robust commercial infrastructure to make XPOVIO® more accessible to patients throughout the mainland. As Antengene aims to have XPOVIO® listed on the National Reimbursement Drug List (NRDL) in the near future and considers the wide range of indications XPOVIO® can address, ensuring broad availability across cities, hospitals, and prescribers is crucial. The partnership with Hansoh Pharma is expected to enhance XPOVIO®'s accessibility and drive its commercial success in China.

Ms. Yuan Sun, Executive Director of Hansoh Pharma, conveyed the company's enthusiasm for this collaboration and commitment to expanding access to XPOVIO® for patients in China. She highlighted XPOVIO®'s considerable commercial potential, particularly in addressing unmet medical needs for hematologic patients. Notably, XPOVIO® has received approvals in various global regions for treating multiple myeloma and diffuse large B-cell lymphoma, with additional potential in myelofibrosis, endometrial cancer, and T/NK-cell lymphoma indications. Hansoh Pharma's goal is to collaborate closely with Antengene to bring XPOVIO® to a broad spectrum of Chinese patients with hematological malignancies.

According to the collaboration agreement, Antengene will retain responsibility for research and development, regulatory approvals, product supply, and distribution of XPOVIO®, while Hansoh Pharma will exclusively handle its commercialization in mainland China. Antengene is set to receive upfront payments totaling up to RMB200 million, with RMB100 million received upon signing. Additionally, subject to the agreement's terms, Antengene may receive up to RMB100 million in remaining upfront payments and up to RMB535 million in milestone payments from Hansoh Pharma. Importantly, Antengene will continue to record revenues from XPOVIO® sales, with Hansoh Pharma charging a service fee.

XPOVIO® stands as the world's first orally-available, selective XPO1 inhibitor, boasting a novel mechanism of action, rapid onset, and lasting responses. By inhibiting the nuclear export protein XPO1, XPOVIO® promotes intranuclear accumulation and activation of tumor suppressor and growth-regulating proteins while reducing levels of oncogenic proteins. Its antitumor effects are achieved through three pathways: enhancing tumor suppressor protein accumulation, reducing oncogenic protein levels in the cytoplasm, and restoring hormone sensitivity via glucocorticoid receptors. Antengene is currently conducting eight clinical studies of XPOVIO® in mainland China, investigating its potential across a range of hematologic malignancies and solid tumors.

In terms of approvals, XPOVIO® is approved in South Korea for multiple myeloma and diffuse large B-cell lymphoma indications. In mainland China and Taiwan, it is approved for treating relapsed or refractory multiple myeloma. Its diverse indications reflect its potential impact across various hematological malignancies.

Report Abuse